| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 48.94% | Morgan Stanley | $3 → $3.5 | Maintains | Equal-Weight |
| 08/11/2023 | 27.66% | Morgan Stanley | $5 → $3 | Maintains | Equal-Weight |
| 08/10/2023 | 70.21% | BTIG | $10 → $4 | Maintains | Buy |
| 06/15/2023 | 112.77% | Morgan Stanley | → $5 | Initiates Coverage On | → Equal-Weight |
| 05/24/2023 | 325.53% | BTIG | → $10 | Upgrades | Neutral → Buy |
| 11/10/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 11/10/2021 | 751.06% | SVB Leerink | $26 → $20 | Maintains | Outperform |
| 08/10/2021 | 963.83% | Credit Suisse | $24 → $25 | Maintains | Outperform |
| 05/11/2021 | 1006.38% | SVB Leerink | $27 → $26 | Maintains | Outperform |
| 03/17/2021 | 836.17% | SVB Leerink | $19 → $22 | Maintains | Outperform |
| 01/20/2021 | 453.19% | SVB Leerink | $10 → $13 | Maintains | Outperform |
| 01/07/2021 | 282.98% | Credit Suisse | $8 → $9 | Maintains | Outperform |
| 11/18/2020 | 325.53% | SVB Leerink | $9 → $10 | Maintains | Outperform |
| 11/10/2020 | 240.43% | Credit Suisse | $7 → $8 | Maintains | Outperform |
| 08/11/2020 | 282.98% | SVB Leerink | $7 → $9 | Maintains | Outperform |
| 05/12/2020 | 197.87% | SVB Leerink | $8 → $7 | Maintains | Outperform |
| 04/09/2020 | 240.43% | BTIG | $9 → $8 | Maintains | Buy |
| 01/10/2020 | 282.98% | SVB Leerink | → $9 | Initiates Coverage On | → Outperform |
| 08/26/2019 | — | Credit Suisse | Reinstates | → Outperform | |
| 05/02/2019 | 282.98% | Credit Suisse | → $9 | Initiates Coverage On | → Outperform |
| 04/17/2019 | 368.09% | Oppenheimer | → $11 | Initiates Coverage On | → Outperform |
| 04/12/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 04/11/2019 | 368.09% | SunTrust Robinson Humphrey | → $11 | Initiates Coverage On | → Buy |
What is the target price for Organogenesis Hldgs (ORGO)?
The latest price target for Organogenesis Hldgs (NASDAQ: ORGO) was reported by Morgan Stanley on November 14, 2023. The analyst firm set a price target for $3.50 expecting ORGO to rise to within 12 months (a possible 48.94% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Organogenesis Hldgs (ORGO)?
The latest analyst rating for Organogenesis Hldgs (NASDAQ: ORGO) was provided by Morgan Stanley, and Organogenesis Hldgs maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Organogenesis Hldgs (ORGO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organogenesis Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organogenesis Hldgs was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Organogenesis Hldgs (ORGO) correct?
While ratings are subjective and will change, the latest Organogenesis Hldgs (ORGO) rating was a maintained with a price target of $3.00 to $3.50. The current price Organogenesis Hldgs (ORGO) is trading at is $2.35, which is out of the analyst's predicted range.
